SAB Biotherapeutics, Inc.
SAB Biotherapeutics (Nasdaq: SABS) is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin therapies for immune and autoimmune disorders, led by SAB-142, a candidate for type 1 diabetes. Its proprietary platform uses genetically engineered transchromosomic cattle to produce… From the company’s description.
In fiscal 2025, SAB Biotherapeutics, Inc. reported net income of $13.27M. Operations used $44.78M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SAB Biotherapeutics, Inc. does
In the company’s own words
SAB Biotherapeutics (Nasdaq: SABS) is a clinical-stage biopharmaceutical company developing multi-specific human immunoglobulin therapies for immune and autoimmune disorders, led by SAB-142, a candidate for type 1 diabetes. Its proprietary platform uses genetically engineered transchromosomic cattle to produce targeted human antibodies without human donors or convalescent plasma; the company also plans to apply the platform to other autoimmune diseases. SAB-142 is being evaluated in a global Phase 2b study in adults, adolescents and children with new-onset Stage 3 type 1 diabetes. The company develops and manufactures its candidates using in-house research, plasma fractionation and purification facilities, and relies on specialized facilities to house the cattle and collect plasma. SAB Biotherapeutics has no reportable business segments described in the provided business information. Its website is https://sabcotherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- MIAMI BEACH, FL
- Fiscal year end
- December
- CIK
- 1833214
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SAB Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SAB Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SAB Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SAB Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SAB Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”